Mabpharm Limited
Research Mabpharm Limited (2181.HK) on Bullrun: market cap HKD 2.06B, P/E 25.0. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2181.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 2.06B
- P/E25.0
- Financial periodFY2025
- RevenueCNY 646.10M
- Revenue growth150.2%
- Net incomeCNY 57.13M
- Free cash flow-CNY 23.22M
- Gross margin88.8%
Valuation Snapshot
latest market cap is HKD 2.06B; P/E is 25.0.
Peer valuation comparison
Latest P/E is 25x versus a Healthcare sector median of 21.69x (15.2% above).
Latest P/E is 25x versus a China median of 16.26x (53.7% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 646.10M | CNY 57.13M | -CNY 23.22M | 88.8% | n/a | CNY 109.26M | CNY 326.74M | CNY 157.30M |
| FY2024 | CNY 258.23M | -CNY 127.95M | -CNY 63.58M | 85.0% | -0.03 | CNY 89.34M | CNY 311.59M | CNY 88.93M |
| FY2023 | CNY 87.16M | -CNY 209.36M | CNY 38.35M | 86.3% | -0.05 | CNY 173.35M | CNY 260.07M | CNY 205.06M |
| FY2022 | CNY 55.92M | -CNY 210.82M | -CNY 182.01M | 72.5% | -0.05 | CNY 33.57M | CNY 126.34M | CNY 400.94M |
| FY2021 | n/a | n/a | n/a | n/a | -0.07 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 2.06B | 25.0 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Mabpharm Limited
Mabpharm Limited, a biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People's Republic of China. It offers CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Mabpharm Limited's market cap?
Mabpharm Limited's market capitalization is HKD 2.06B.
What is Mabpharm Limited's P/E ratio?
Mabpharm Limited's price-to-earnings (P/E) ratio is 25.0.
What does Mabpharm Limited do?
Mabpharm Limited, a biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People's Republic of China.